The role of macroscopic on-site evaluation in the era of biopsy needles: is it still useful?
Endoscopy · 01.02.2023 · 55 (02) · 138-139
DOI: 10.1055/a-1942-6382 ↗Kurz gefasst
Editorial in der Zeitschrift Endoscopy, erschienen am 01.02.2023. Verfasst von Hirotoshi Ishiwatari. Beteiligte Einrichtung: Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan. Hauptthemen laut MEDLINE: Needles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
10.1055/a-1915-5263 Macroscopic on-site evaluation (MOSE) involves visual assessment of samples obtained during endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). In brief, the presence or length of the macroscopically visible core is investigated to decide whether an appropriate sample for pathological evaluation has been obtained [ 1 ] [ 2 ]. The approach is similar to that of rapid on-site evaluation (ROSE), which differs from MOSE in terms of cytological evaluation. ROSE overcomes the disadvantage of EUS-FNA, in which more than three or four needle passes are required for sufficient diagnostic accuracy, by reducing the number of needle passes [ 3 ]. However, because of limited pathology staffing, ROSE has not been implemented in many hospitals, especially in Europe and Asia. MOSE may therefore be an alternative in such situations [ 1 ] [ 2 ]. A prospective study of 19G standard needles revealed that a macroscopically visible core length of ≥ 4 mm can be an indicator of specimen adequacy [ 2 ]. Furthermore, a randomized controlled trial (RCT) using this criterion showed that EUS-FNA with MOSE provided a similar diagnostic yield to EUS-FNA without MOSE with fewer needle passes (2 vs. 3; P 95 % was achieved with two needle passes, demonstrating that two passes are sufficient when using a 22G Franseen needle in clinical practice [ 8 ] [ 9 ]. The Achilles’ heel of MOSE is false positives as the macroscopically visible core can contain normal tissue, such as fibrous tissue and pancreatic parenchyma, and discrimination between this and tumor tissue is impossible. The aim of measuring the macroscopically visible core length is to reduce the possibility of false positives and, although it is useful, it does not guarantee an accuracy of 100 %. In fact, false positives occurred in 6.9 % (13/190) of the MOSE group in this study. In nine of these 13 patients, a correct diagnosis was obtained by additional passes after the macroscopically visible core length had reached 10 mm, and the accuracy rate increased from 90.0 % to 94.7 %. In other words, these nine patients would have been disadvantaged without additional passes. Considering this, it may not be realistic for the procedure to be terminated after one needle pass based on the MOSE result. When performing EUS-FNB with 22G Franseen needles, rather than using MOSE to reduce the number of needle passes, it may be better to always perform two needle passes without MOSE to save on the labor required to perform MOSE. Therefore, an RCT with two needle passes in the control group would be more meaningful for clinical practice. Comprehensive genome profiling (CGN) using next-generation sequencing has been used clinically for solid tumors, and genotype-matched therapies provide improved prognoses. A larger sample size is required for this test compared with that required for pathological diagnosis. Therefore, more needle passes are probably needed in EUS-FNB, which might lead to an increased rate of adverse events or become a burden on endoscopists. A prospective study showed that measurement of the macroscopically visible core can predict the quantity of sample obtained when using a 22G Franseen needle, indicating the possibility of reducing the number of needle passes by using MOSE when samples are to be submitted to CGN [ 9 ]. The sample quantity cannot be evaluated by ROSE, and the prediction of tissue quantity plays a role only in MOSE. As a result, the role of MOSE may have changed in the era of new biopsy needles. Publication History Article published online: 10 October 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany Refers to: Endoscopic ultrasound-guided fine-needle biopsy with or without macroscopic on-site evaluation: a randomized controlled noninferiority trial Endoscopy 2023; 55(02): 129-137 DOI: 10.1055/a-1915-5263
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Zitieren
APA
Ishiwatari, H. (2023). The role of macroscopic on-site evaluation in the era of biopsy needles: is it still useful?. Endoscopy, 55(02), 138-139. https://doi.org/10.1055/a-1942-6382
Vancouver
Ishiwatari H. The role of macroscopic on-site evaluation in the era of biopsy needles: is it still useful?. Endoscopy. 2023;55(02):138-139. doi:10.1055/a-1942-6382
BibTeX
@article{Ishiwatari2023,
author = {Ishiwatari, Hirotoshi},
title = {The role of macroscopic on-site evaluation in the era of biopsy needles: is it still useful?},
journal = {Endoscopy},
year = {2023},
volume = {55},
number = {02},
pages = {138--139},
doi = {10.1055/a-1942-6382}
}
EUVIMED